Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Mycobacterium tuberculosis | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase BioA | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Mycobacterium leprae | Probable 4-aminobutyrate aminotransferase GabT (GAMMA-AMINO-N-BUTYRATE TRANSAMINASE) (GABA TRANSAMINASE) (GLUTAMATE:SUCCINIC SEM | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase BioA | 437 aa | 397 aa | 28.5 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.1082 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.1082 | 1 |
Mycobacterium ulcerans | hypothetical protein | 0.0184 | 0.5153 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.0027 | 0 | 0.5 |
Onchocerca volvulus | 0.0048 | 0.0691 | 0.5 | |
Mycobacterium leprae | PROBABLE ADENOSYLMETHIONINE-8-AMINO-7-OXONONANOATE AMINOTRANSFERASE BIOA | 0.0184 | 0.5153 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.0027 | 0 | 0.5 |
Mycobacterium tuberculosis | Probable aminotransferase | 0.0184 | 0.5153 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.1082 | 1 |
Schistosoma mansoni | cellular tumor antigen P53 | 0.0048 | 0.0691 | 1 |
Mycobacterium ulcerans | adenosylmethionine-8-amino-7-oxononanoate aminotransferase | 0.0184 | 0.5153 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.0453 | 0.419 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.0027 | 0 | 0.5 |
Mycobacterium tuberculosis | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase BioA | 0.0184 | 0.5153 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.0453 | 0.419 |
Leishmania major | hypothetical protein, conserved | 0.0027 | 0 | 0.5 |
Trichomonas vaginalis | acetylornithine aminotransferase, putative | 0.0184 | 0.5153 | 0.5 |
Echinococcus multilocularis | tumor protein p63 | 0.033 | 1 | 0.5 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.0027 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0048 | 0.0691 | 0.6391 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.0027 | 0 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.1082 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
AC50 (functional) | 0.659 uM | PubChem BioAssay. Mycobacterium tuberculosis BioA enzyme inhibitor Measured in Biochemical System Using Plate Reader - 2163-02_Inhibitor_Dose_CherryPick_Activity. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 2.2387 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 11.6891 uM | PUBCHEM_BIOASSAY: Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488745, AID488752, AID488774, AID504848, AID504850] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Plasmodium falciparum | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.